Abstract: Compounds of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.
Type:
Grant
Filed:
June 11, 2021
Date of Patent:
January 9, 2024
Assignee:
Pfizer Inc.
Inventors:
Markus Boehm, Shawn Cabral, Matthew S. Dowling, Kentaro Futatsugi, Kim Huard, Esther Cheng Yin Lee, Allyn T. Londregan, Jana Polivkova, David A. Price, Qifang Li
Abstract: The invention relates to a method of treating a MEK-associated tumor by administering to a subject in need thereof a therapeutically effective amount of a solid form 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.
Type:
Application
Filed:
September 18, 2023
Publication date:
January 4, 2024
Applicant:
Pfizer Inc.
Inventors:
Shelley ALLEN, Patrick Michael DOERNER BARBOUR, James Francis BLAKE, Sydney Taylor BLANCHE, Mark Laurence BOYS, Wesley Dewitt CLARK, Connor James COWDREY, Joshua Ryan DAHLKE, Alex Andrew KELLUM, Ellen Margaret KNAPP, David Austin MORENO, Jacob Matthew O'LEARY, Li REN, Faith Elizabeth WITKOS, Jennifer Lynn FULTON
Abstract: This invention relates to combination therapies comprising a cyclin dependent kinase 4 (CDK4) inhibitor of Formula (I) or a pharmaceutically acceptable salt thereof, and an antiandrogen, optionally in further combination with an additional anti-cancer agent, and associated methods of treatment, pharmaceutical compositions, and uses thereof.
Type:
Application
Filed:
August 10, 2021
Publication date:
January 4, 2024
Applicants:
Pfizer Inc., Astellas Pharma Inc.
Inventors:
Lars ANDERS, Kimberly Hyunjung KIM, Danan LI, Elizabeth Anne MCMILLAN, Robert Andrew ROLLINS, Brendan Ayers VEENEMAN
Abstract: The invention relates to antibodies, or antigen-binding fragments thereof, that specifically binds to interferon beta (IFN?). Such antibodies, or antigen-binding fragments thereof, are are useful for various therapeutic or diagnostic purposes.
Type:
Grant
Filed:
November 9, 2020
Date of Patent:
January 2, 2024
Assignees:
Pfizer Inc., The Brigham And Women's Hospital, Inc.
Inventors:
Stefano V. Gulla, Christine Huard, Janet Elizabeth Buhlmann, Juan Carlos Almagro, Sreekumar R. Kodangattil, Steven A. Greenberg, Edward Roland Lavallie, Eric M. Bennett, Lidia Mosyak, James Perry Hall, Anthony John Coyle
Abstract: The present invention comprises mutants of a wild-type cytomegalovirus (CMV) glycoprotein B (gB) protein that include at least two introduced amino acid mutations relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB), compositions including the mutants and uses thereof. In some embodiments, the mutant is stabilized in a conformation alternative to the gB postfusion conformation.
Type:
Grant
Filed:
June 17, 2021
Date of Patent:
January 2, 2024
Assignee:
Pfizer Inc.
Inventors:
Yuhang Liu, Ye Che, Xiaoyuan Sherry Chi, Philip Ralph Dormitzer, Jennifer Anne Nicki, Xiaojie Yao
Abstract: Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, and 7-aza-benzimidazoles as GLP-1R agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.
Type:
Grant
Filed:
June 13, 2019
Date of Patent:
January 2, 2024
Assignee:
Pfizer Inc.
Inventors:
Gary Erik Aspnes, Scott W. Bagley, Edward L. Conn, John M. Curto, David J. Edmonds, Mark E. Flanagan, Kentaro Futatsugi, David A. Griffith, Kim Huard, Chris Limberakis, Alan M. Mathiowetz, David W. Piotrowski, Roger B. Ruggeri
Abstract: A pharmaceutical soft gelatin capsule dosage form comprising a soft gelatin shell and a fill, wherein: (a) the soft gelatin shell comprises gelatin and at least one plasticizer; and (b) the fill comprises an anti-oxidant, at least one solvent, and talazoparib or a pharmaceutically acceptable salt thereof. Said pharmaceutical composition for use in treating cancer.
Type:
Application
Filed:
November 11, 2021
Publication date:
December 28, 2023
Applicant:
PFIZER INC.
Inventors:
Alan Francis CARMODY, Lydie Claude Sylvie PAIRET
Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
Type:
Application
Filed:
January 20, 2023
Publication date:
December 21, 2023
Applicant:
Pfizer Inc.
Inventors:
Elaine GREER, Stephen ANDERSON, Mark MALONEY, Shu YU, Ekaterina ALBERT, Emily RIGSBEE
Abstract: Described herein are pharmaceutical compositions comprising 2-{5-[(3-ethoxypyridin-2-yl)oxy]pyridin-3-yl}-N-[(3S,5S)-5-fluoropiperidin-3-yl]pyrimidine-5-carboxamide, or pharmaceutically acceptable salt thereof, for treatment of liver disease and diseases related thereto. Also described are compositions comprising 2-{5-[(3-ethoxypyridin-2-yl)oxy]pyridin-3-yl}-N-[(3S,5S)-5-fluoropiperidin-3-yl]pyrimidine-5-carboxamide, or pharmaceutically acceptable salt thereof and 4-(4-(1-Isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4?-piperidine]-1?-carbonyl)-6-methoxypyridin-2-yl)benzoic acid, or pharmaceutically acceptable salt thereof, for treatment of liver disease and diseases related thereto.
Type:
Application
Filed:
February 22, 2021
Publication date:
December 21, 2023
Applicant:
Pfizer Inc.
Inventors:
Neeta Balkrishan Amin, Arthur James Bergman, Roberto Arnaldo Calle, Robert Gregory Dullea, David James Edmonds, William Paul Esler, Kevin James Filipski, James Richard Gosset, Albert Myung Kim, Jeffrey Allen Pfefferkorn, Patrick Robert Verhoest
Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
Type:
Grant
Filed:
February 17, 2023
Date of Patent:
December 19, 2023
Assignee:
PFIZER INC.
Inventors:
Elaine Greer, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee
Abstract: A pharmaceutical formulation for parental use comprising testosterone cypionate with a concentration of 200 mg/mL, benzyl benzoate with a concentration of 25%-35% v/v, cottonseed oil, and a preservative. A pharmaceutical product comprising a vial containing said formulation. A kit which comprises said pharmaceutical product and a package insert that is free of instructions to warm and shake the vial.
Abstract: The present invention relates to antibodies that specifically bind to B7-H4 (B7 Homology 4, encoded by gene VTCN1) and bispecific antibodies that specifically bind to both B7-H4 and CD3 (Cluster of Differentiation 3), and polynucleotides, pharmaceutical compositions and methods and uses thereof.
Type:
Grant
Filed:
July 16, 2021
Date of Patent:
December 12, 2023
Assignee:
Pfizer Inc.
Inventors:
James Reasoner Apgar, Andrea Therese Hooper, Malgorzata Agnieszka Nocula-Lugowska, Lei Wu
Abstract: A parenteral aqueous suspension formulation for corticosteroids without polyethylene glycol (PEG) or Polysorbate (PS) that has better resuspendability, longer stability compared to commercially available formulations, and additionally allows for stable formulations of higher concentrations of corticosteroids that were not previously feasible. Preferably, the corticosteroid is methylprednisolone acetate or medroxyprogesterone acetate.
Type:
Application
Filed:
October 19, 2021
Publication date:
December 7, 2023
Applicant:
Pfizer Inc.
Inventors:
Omar Abdelrahman Salman, Joel Aaron Bergman
Abstract: The present invention provides antibodies and antibody-drug conjugates that bind to the extra domain B splice variant of fibronectin 1 and methods for preparing and using the same.
Type:
Grant
Filed:
February 9, 2023
Date of Patent:
December 5, 2023
Assignee:
Pfizer Inc.
Inventors:
Andrea Therese Hooper, Kimberly Ann Marquette, Chakrapani Subramanyam, Hans-Peter Gerber, Chad Michael May
Abstract: Compounds of the general formula (I): or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
Type:
Application
Filed:
July 24, 2023
Publication date:
November 30, 2023
Applicant:
PFIZER INC.
Inventors:
Martin James WYTHES, Indrawan James MCALPINE, Ryan PATMAN, Eugene Yuanjin RUI, Andrew FENSOME, Andreas MADERNA, Mehran JALAIE, Ketan S. GAJIWALA
Abstract: The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, R2 and R3 are as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).
Type:
Application
Filed:
May 24, 2023
Publication date:
November 30, 2023
Applicant:
Pfizer Inc.
Inventors:
Ariamala Gopalsamy, Shawn Cabral, Agustin Casimiro Garcia, Ming Zhu Chen, Chulho Choi, Robert Lee Dow, Olugbeminiyi Omezia Fadeyi, David Hepworth, Jayasankar Jasti, Lyn Howard Jones, Arjun Venkat Narayanan, Mihir Dineshkumar Parikh, David Walter Piotrowski, Lee Richard Roberts, Ralph Pelton Robinson, Jr., Hatice Gizem Yayla
Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.
Type:
Grant
Filed:
January 27, 2023
Date of Patent:
November 21, 2023
Assignee:
PFIZER INC.
Inventors:
Elaine Greer, Stephen Anderson, Mark Maloney, Shu Yu, Ekaterina Albert, Emily Rigsbee
Abstract: Antibodies that specifically bind to LTBR are provided. Also provided are uses of these antibodies, and related compositions and methods.
Type:
Application
Filed:
May 10, 2023
Publication date:
November 16, 2023
Applicant:
Pfizer Inc.
Inventors:
James Reasoner APGAR, Bas Joannes Gertrudis BAATEN, Aruna BITRA, Javier Fernando CHAPARRO RIGGERS, Giuseppe DI CARO, Pawel Kamil DOMINIK, Zachary John MABEN, Lidia MOSYAK, Andrew Ross NAGER, Cecilia Marianne ODERUP, Edward Derrick PASCUA, Shahram SALEK-ARDAKANI, Dirk Michael ZAJONC
Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
Type:
Grant
Filed:
August 27, 2020
Date of Patent:
November 14, 2023
Assignee:
PFIZER INC.
Inventors:
Tracy Chia-Chien Kuo, Javier Fernando Chaparro Riggers, Wei Chen, Amy Shaw-Ru Chen, Edward Derrick Pascua, Thomas John Van Blarcom, Leila Marie Boustany, Weihsien Ho, Yik Andy Yeung, Pavel Strop, Arvind Rajpal